Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) insider Pierre Sayad sold 12,000 shares of the firm's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of C$17.18, for a total value of C$206,160.00. Following the transaction, the insider directly owned 9,519 shares in the company, valued at approximately C$163,536.42. This represents a 55.76% decrease in their position.
Fennec Pharmaceuticals Stock Down 1.8%
Shares of FRX stock opened at C$17.10 on Wednesday. The stock's 50-day moving average price is C$15.52 and its 200 day moving average price is C$12.66. The stock has a market capitalization of C$599.65 million, a PE ratio of -142.50 and a beta of 3.72. Fennec Pharmaceuticals Inc. has a 52-week low of C$7.59 and a 52-week high of C$17.64.
Institutional Investors Weigh In On Fennec Pharmaceuticals
An institutional investor recently bought a new stake in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. purchased a new position in shares of Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 105,000 shares of the biopharmaceutical company's stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned 0.30% of Fennec Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 15.40% of the company's stock.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
